sector medic suppli devic
 differenti cgm approach
potenti creat signific valu initi buy
messag initi coverag buy rate pt
see eversens long-term implant system differenti new entrant
cgm market one expect appeal diabet patient look
avoid drawback short-term transcutan sensor time cgm
technolog evolv rapidli feedback physician patient survey suggest
potenti captur meaning share eversens roll
 later year creat signific sharehold valu process
believ continu glucos monitor cgm way becom
standard care insulin-depend diabet nearli year sinc
introduct countless studi valid advantag cgm tradit point-
in-tim blood glucos test reduc critic factor manag
diabet yet despit compel clinic evid support use penetr remain
rel low today type popul less
insulin-intens type patient mani factor contribut lacklust adopt
view includ inconsist sensor accuraci conveni qualiti life issu
high increment cost therapi recent advanc address mani
histor shortcom technolog pave way increas penetr
amid period rapid innov across broader cgm landscap see
senseon eversens differenti technolog tradit cgm system
featur transcutan sensor must swap everi day
approach proven effect method measur interstiti glucos level
sever drawback includ risk infect skin irrit weekli sensor
insert conspicu natur sensor/transmitt patient bodi
case need carri separ receiv alert glucos excurs
eversens address mani issu sensor implant subcutan
quick office-bas procedur provid accur glucos read month
need replac extern transmitt power sensor calcul
glucos valu send inform mobil app user phone also
deliv on-bodi vibe alert glucos level cross certain threshold
transmitt taken reattach need patient free take short cgm
feedback physician diabet patient suggest us senseon
potenti take meaning share cgm market eversens
roll later year last week fda advisori panel meet panelist vote
unanim system safeti efficaci well-demonstr
potenti benefit outweigh risk believ set senseon receiv
like fda approv next month recent survey type diabet
current use competit cgm system said would either like
like tri eversens approv meanwhil endocrinologist
spoke estim cgm patient would consid switch
think figur like overst true opportun share gain
near term believ speak intrins valu patient see eversens novel
form factor model assum captur
intern cgm patient instal base next four year respect
even modest penetr enough drive overal revenu growth
initi buy price target base multipl sale
estim discount back rate impli upsid current level
page analyst certif import disclosur
senseon germantown md base medic devic compani focus
develop novel continu glucos monitor technolog aid treatment
manag diabet compani eversens system receiv ce mark
featur first commerci avail long-term implant cgm sensor launch
follow septemb european approv eversens xl extend
sensor lifespan day day last week fda advisori panel
vote unanim benefit eversens outweigh risk pave way
anticip launch sensor later year believ eversens
repres differenti new entrant world-wide cgm market
potenti signific appeal patient
date commerci activ limit european sale
distribut partner roch also own equiti stake compani rubin
medic compani gener revenu
estim eversens instal base patient
model call sale ramp driven
expect launch continu eu penetr forecast assum
captur share intern cgm market
respect forecast believ could prove conserv base feedback
recent survey high-volum endocrinologist type diabet patient
figur revenu composit million
compani report guggenheim secur estim
page analyst certif import disclosur
clinic valu cgm proven numer studi insulin-depend
diabet must test blood sugar regularli throughout day tradit
done prick finger insert test strip drop blood self-
monitor blood glucos meter smbg read use determin insulin
dose patient usual inject multipl time day stay
within normal glucos rang challeng approach point-in-tim
blood glucos estim provid strip meter test provid inform
trend matter dilig patient use meter still obtain
small number read cours day
figur summari cgm clinic efficaci result
continu glucos monitor address shortcom smbg cgm system
use transcutan sensor test glucos level interstiti fluid skin
sensor worn bodi attach transmitt relay glucos read
handheld receiv and/or smartphon new read taken everi minut
throughout day provid patient near real-tim visibl glucos
level trend facilit better manag diseas cgm util
shown result greater decreas surrog measur patient
averag blood glucos level three month period smbg alon figur
show find independ type insulin deliveri multipl daili
inject insulin pump even small drop correl signific
reduct mani concomit risk factor associ diabet see
strong evid favor establish cgm standard care insulin-depend
eversens build success tradit cgm system elimin
drawback transcutan sensor eversens sensor size
grain rice implant skin upper arm quick office-bas
procedur local anesthesia special design implant tool on-bodi
transmitt worn top sensor power transcutan rf
energi unlik tradit cgm system use enzymat electrochem
reaction measur interstiti glucos level eversens employ optic sensor
special polym fluoresc presenc glucos intens fluoresc
vari depend quantiti interstiti glucos present time sensor
measur fluctuat commun data wirelessli transmitt
transmitt convert data estim blood glucos valu sent
along trend inform alert mobil app user phone and/or
parent caregiv transmitt also provid on-bodi vibrat alert notifi
patient glucos level reach certain pre-defin threshold sensor accuraci
check time smbg calibr daili user notifi roughli
day deterior past accept level old sensor remov
physician new one implant
page analyst certif import disclosur
figur eversens mechan action
see multipl potenti advantag approach first patient longer
worri insert new sensor everi day requir certain
level dilig part user also carri risk skin irrit
possibl infect time second transmitt remov
reattach time without impact sensor patient freedom go short
period time without visibl sign diseas person cgm
holiday particularli import younger activ patient may
want sensor/transmitt visibl work bath suit patient
glucos level would monitor period believ ad flexibl
valu differenti eversens cgm system requir patient
throw function sensor open new one wish go without
extern system compon time final on-bodi vibrat alert featur
eversens transmitt mean patient manag diseas even arent
close proxim phone ad anoth layer person freedom
senseon launch version eversens europ late follow
sensor eversens xl septemb precis ii pivot trial
eversens demonstr impress accuraci mard
entir period meanwhil match data point within mg/dl
refer test read mg/dl refer read
mg/dl within figur show stat stack well
commerci approv cgm system
march fda conven meet clinic chemistri clinic toxicolog
devic panel discuss data potenti issu could aris
eversens uniqu form factor approv overal thought panel
deliber posit major concern rais end panel vote
unanim suffici evid eversens safeti efficaci
clinic benefit technolog outweigh possibl risk agenc
requir follow advic advisori panel believ make highli probabl
receiv fda approv like time sometim next
page analyst certif import disclosur
compani report fda summari safeti effect
feedback recent patient survey suggest implant sensor could
signific appeal among current cgm user sampl includ type
diabet live includ current cgm user ask
cgm patient like would tri eversens becom avail two
third said would either like like test compar
indic would unlik unlik tri meanwhil
physician spoke estim cgm patient would like switch
eversens also ask doc whether agre statement
train compani would comfort perform eversens sensor
implant remov see potenti hurdl adopt sinc mani
endocrinologist dont perform procedur part daili practic yet said
either agre strongli agre statement
figur would doc comfort cgm implant
view data point encourag believ like
overestim senseon true opportun near-term market share gain one
thing patient say theyr like tri new technolog quit anoth
actual schedul appoint doctor implant place arm
immedi post launch also contend challeng
build sale organ scratch reli third parti distribut
partner roch rubin medic europ
page analyst certif import disclosur
also import point awar eversens diabet commun
still low today physician respond indic yet
familiar technolog provid brief descript product
group survey particip would expect patient physician percept evolv
substanti commerci launch play
longer term work number enhanc augment
eversens util first sensor first version product
launch expect compani begin enrol trial eversens
xl soon initi approv put version track potenti launch
senseon talk fda reduc number requir calibr xl
label daili less frequent longer term compani believ
eventu transit sensor requir weekli calibr
would view compel product offer patient
compani report fda summari safeti effect
eversens novel form factor could also lend number treatment
approach one compani discuss flash glucos monitor
configur analog abbott freestyl libr patient would scan
sensor phone download glucos data intermitt rather wear
transmitt eversens alreadi capabl kind data transfer believ
calibr requir system would come dramat
competit libr factori calibr could also issu although
see potenti better posit weather price pressur
competitor due longev sensor requir produc far fewer
durat patient support
interest concept view compani gemini project approach
would allow patient altern flash continu monitor perhap use
flash mode discret glucos measur day wear
transmitt night increas peac mind sleep manag hasnt
yet announc expect regulatori timelin gemini believ visibl front
could improv next year
page analyst certif import disclosur
estim world-wide cgm market top grow
clip receiv fda approv first profession cgm system
effort recent confin promot cgm
adjunct featur insulin pump franchis develop sensor-
augment pump left non-pump segment market estim
account roughli third cgm patient meanwhil
think pump segment market split roughli
last year net result share posit cgm
figur estim cgm revenu market share geographi
compani report guggenheim secur llc estim
libr enter fray physician spoke expect lose
signific share overal respond forecast point share loss
abbott pick strength roll-out
page analyst certif import disclosur
abbott alreadi made impress gain intern libr launch late
sale top give abbott estim share ou cgm
market dollar basi closer term patient therapi addit
appeal featur technolog discuss import note libr
also benefit signific reimburs advantag europ tradit
cgm cover countri germani except payer much
quicker embrac lower cost flash glucos monitor option result dont
view intern libr experi good proxi could see domest
model call abbott gain point market share end
year overal patient instal base model gain come
evenli point point forecast
assum pace new libr patient addit actual slow
averag per quarter balanc year abbott experi
attrit rate vs also assum materi acceler
market growth net patient gain vs drive growth
 instal base
meanwhil although made limit inroad europ date
believ potenti disrupt go forward estim
compani intern instal base stood patient
progress made back half year distribut partner begin
expand market expect number rise end
close would repres share ou cgm
market unit state model new patient start
domest instal base grow patient share
endocrinologist spoke also bullish potenti
increas adopt next year note group report
higher cgm penetr today within practic believ reflect
 market broadli adopt among type patient today vs
nationwid nonetheless view forecast cgm util rise adult
pediatr patient three year encourag data point
comparison model assum penetr climb
page analyst certif import disclosur
stori similar type side estim overal penetr stand
today vs respond report within insulin-intens
popul estim non-intens patient physician expect
cgm util among type patient practic climb
group respect compar forecast type
penetr rise insulin-intens popul estim dont current
alloc util non-intens group
model ww cgm revenu grow driven annual growth
patient instal base slower compound-annual-growth-rate market post
much explos growth driven libr rapid adopt
intern phenomenon dont expect repeat degre
assumpt patient instal base assum acceler gain
growth moder back back end
forecast period
compani report factset guggenheim secur llc estim
page analyst certif import disclosur
million use market market revenu growth medic suppli devic
diabet global epidem accord american diabet associ
american diabet popul preval
medicare-ag popul even higher rank seventh lead caus
death nationwid cite underli caus nearli case health
burden exert tremend financi toll total cost diagnos diabet
estim includ direct medic expens
lost product global world organ estim adult
diabet figur quadrupl sinc diseas contribut
death year
diabet patient typic broken two main subgroup type diabet
suffer underli immun disord caus bodi cell target
beta cell pancrea produc insulin caus condit unknown
believ deriv combin genet environment factor type
patient usual diagnos children ada estim roughli
type patient today cure type diabet patient
requir take lifelong regimen synthet insulin inject surviv
type diabet acquir metabol disord character increas insulin
resist although pancrea continu produc insulin total beta cell output may
also depress genet factor play role determin person suscept
type diabet usual caus obes lack exercis poor dietari habit
result treatment type diabet gener begin recommend lifestyl
chang unsuccess patient progress drug therapi eventu insulin-
intens treatment estim american suffer type
diabet insulin depend
diabet number seriou health consequ without insulin bodi lose
abil regul blood sugar lead episod hyperglycemia high blood
glucos hypoglycemia low blood glucos hyperglycemia gener defin
blood glucos level mg/dl associ increas long-term risk
cardiovascular renal neurolog vision disord hypoglycemia mg/dl
acut issu brain requir continu suppli glucos function properli
earli symptom hypoglycem episod may includ dizzi confus rapid
heartrat treat lead seizur loss conscious even death
page analyst certif import disclosur
technolog effect manag diabet rapidli evolv insulin-depend
diabet must test blood sugar regularli throughout day tradit
done prick finger insert test strip drop blood self-
monitor blood glucos meter smbg read use determin insulin
dose patient usual inject multipl time day stay
within normal glucos rang challeng approach point-in-tim
blood glucos estim provid strip meter test provid inform
trend matter dilig patient use meter still obtain
small number read cours day
continu glucos monitor address shortcom smbg cgm system
use transcutan sensor test glucos level interstiti fluid skin
sensor worn bodi attach transmitt relay blood sugar
read handheld receiv and/or smartphon new read taken everi
minut throughout day provid patient near real-tim visibl
glucos level trend facilit better manag diseas
figur show exampl patient test four time cours
day two elev read two within normal rang figur
read overlaid cgm data show patient actual spent
vast major day outsid normal rang
page analyst certif import disclosur
